The optimal T cell attributes for adoptive cancer immunotherapy are unclear. Recent clinical trials of ex vivo expanded tumor-infiltrating lymphocytes indicated that differentiated T effector cells can elicit durable anti-tumor responses in some cancer patients, with their anti-tumor activity tightly correlated with their persistence in the host. Thus, there is great interest in the definition of intrinsic biomarkers that can predict the conversion of short-lived tumor antigen-specific T effector cells into long-lived T memory cells. Long-term persistence of ex vivo expanded tumor specific CD8+ T effector clones has been reported in refractory metastatic melanoma patients after adoptive T cell transfer. By utilizing highly homogeneous clone populations from these preparations, we performed a comparative transcriptional profiling to define pre-infusion molecular attributes that can be ascribed to an effector-to-memory transition. Through this route, we discovered that pre-infusion T cell clones which expressed the IL-7 receptor (IL-7R) and c-myc were more likely to persist longer after adoptive transfer to patients. The predictive value of these two biomarkers was strengthened by utilizing IL-7R protein, IL-7 induced pSTAT5, and c-myc mRNA expression to prospectively identify human tumor-specific T effector clones capable of engraftment into immunodeficient mice. Overall, our findings reveal IL-7R and c-myc expression as intrinsic biomarkers that can predict the fate of effector CD8+ T cells after adoptive transfer.